ChemicalBook Product Catalog Natural Products Coumarin BERGAPTOL

BERGAPTOL

Product NameBERGAPTOL
CAS486-60-2
MFC11H6O4
MW202.16
EINECS
MOL File486-60-2.mol

Chemical Properties

Melting point	287-290°C
Boiling point	311.9±11.0 °C(Predicted)
Density	1.526±0.06 g/cm3(Predicted)
storage temp.	Sealed in dry,2-8°C
solubility	DMSO (Slightly), Methanol (Slightly)
pka	6.80±0.20(Predicted)
form	Solid
color	Pale Beige to Pale Brown
BRN	190104
LogP	1.405 (est)

Safety Information

Hazard Codes	Xn
Risk Statements	22-36
Safety Statements	22-24/25-26
WGK Germany	3

Usage And Synthesis

Chemical Properties

White powder, soluble in organic solvents such as methanol, ethanol, and DMSO. It comes from the fruit of Citrus medica L. Var. Sarcodactylis of the Rutaceae family.

Uses

A hydroxylated psoralen that acts as a potent inhibitors of debenzylation activity of CYP3A4 enzyme with an IC50 value of 24.92 and 42.93 μM, respectively. Recent studies suggest that it may have antiproliferative and anticancer properties.

Definition

ChEBI: Bergaptol is a member of psoralens and a 5-hydroxyfurocoumarin. It is a conjugate acid of a bergaptol(1-).

Synthesis

484-20-8

486-60-2

mL) solution in dichloromethane (CH2Cl2, 3.5 mmol) was slowly added dropwise via a glass syringe to a 1 M solution of boron tribromide (BBr3, 4 mmol) in dichloromethane. The reaction mixture was stirred at 0°C for 1-2 hours. Upon completion of the reaction, the reaction was quenched by the addition of crushed ice and the reaction mixture was extracted with dichloromethane (CH2Cl2) and washed several times with water. The organic layers were combined, dried over anhydrous sodium sulfate (Na2SO4) and concentrated to dryness under reduced pressure to give the target phenolic compound.

in vivo

Bergaptol (10-40 mg/kg, i.p., once a day for two weeks) improves the cognitive impairment in LPS-treated mice^[4].

Animal Model:	LPS (40 μg/kg, i.c.v.)-treated mice^[4]
Dosage:	10-40 mg/kg
Administration:	i.p., once a day for two week
Result:	Reduced LPS-induced fixation and cleavage of neuronal nuclei in the CA1 region of the hippocampus (H&E staining). Increasead the dendritic spine density of mice. Inhibited LPS-induced neuroinflammation.

target

CYP3A4

IC 50

CYP3

References

[1] Bioorganic and Medicinal Chemistry Letters, 1997, vol. 7, # 20, p. 2593 - 2598
[2] Organic and Biomolecular Chemistry, 2006, vol. 4, # 8, p. 1604 - 1610
[3] European Journal of Medicinal Chemistry, 2013, vol. 60, p. 155 - 169
[4] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 2, p. 784 - 788
[5] Patent: WO2004/37827, 2004, A1. Location in patent: Page 26

BERGAPTOL

Chemical Properties

Safety Information

Usage And Synthesis

Preparation Products And Raw materials

BERGAPTOL Supplier

BERGAPTOL manufacturers

Related Product Information